AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02386644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound transperineal assessment
Description: Transperineal ultrasound assessment of vaginal canal for pooling of amniotic fluid.
Study NCT02386644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound amniotic fluid index measurement
Description: Calculation of amniotic fluid index in millimetres via ultrasonography by measuring four deepest pockets in four quadrants.
Study NCT02386644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speculum examination
Description: Sterile speculum examination to evaluate vaginal pooling of amniotic fluid pooling.
Study NCT02386644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitrazine test
Description: To assess acid , alkaline status of pooled fluid in vagina.
Study NCT01888302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01888302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01888302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01888302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT02606201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peri sphincter injection Autologous myofibers
Description: The first step of the procedure consists to harvest a muscle fragment from the lower part of the rectus abdominis muscle of the abdomen approached by a short incision. Injectable myofiber cores will be prepared by hydrodissection of the muscle biopsy.~All myofibers cores will be suspended in autologous serum prepared by centrifugation before the incision.~During the second step of the procedure, the myofibers will be injected percutaneously into the peri-sphincter region under endoscopic and radiographic control.
Study NCT01227018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090
Description: Given IV
Study NCT01227018 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiologic imaging
Description: radiologic modalities used to evaluate response to treatment
Study NCT01227018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood draw
Description: Venous blood will be drawn from those patients who give consent. Serum will be used to look for biomarkers predictive of response
Study NCT01851759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinepazide
Description: 2 branches of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.
Study NCT01851759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.
Study NCT01424215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Description: Injection of ICG intravenously then intraoperative imaging of the biliary anatomy during laparoscopic cholecystectomy using a near infrared (NIRF) imaging camera(Spy scope, Novadaq Canada)
Study NCT02904954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenously
Study NCT02904954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Durvalumab plus SBRT
Description: Intravenously plus radiotherapy
Study NCT01417377 — intervention group
Intervention type: DRUG
Intervention: Mircera
Description: Participants with chronic kidney disease receiving methoxy polyethylene glycol-epoetin beta (Mircera) and previously on treatment with short-acting epoetin alpha will be observed for a period of 6 months.
Study NCT01621802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix
Description: One dose administered subcutaneously in the triceps region of the right arm.
Study NCT01621802 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II
Description: One dose administered subcutaneously in the triceps region of the right arm.
Study NCT01621802 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Kinrix
Description: One dose administered by deep intramuscular injection in the upper left deltoid.
Study NCT01621802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kinrix
Description: One dose administered by deep intramuscular injection in the upper left deltoid.
Study NCT01621802 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ProQuad
Description: One dose administered subcutaneously in the triceps region of the left arm.
Study NCT01621802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProQuad
Description: One dose administered subcutaneously in the triceps region of the left arm.
Study NCT02948634 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Phoenix Laser Treatment
Description: Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy. Intervention will take place in the therapy room at the McDermott Center for Pain Management, which is appropriately equipped for laser administration. Application of therapeutic laser will be completed by licensed physical therapists who have completed safety training for therapeutic laser application including appropriate use of safety eyewear, room access, laser signage for laser use, and patient monitoring.
Study NCT02948634 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Phoenix Laser Treatment
Description: The 30 min treatments will include multiple 60 sec applications to all tender points on the spine or extremities and a 10 minute application along the bilateral sympathetic ganglion in the paraspinous region. The treatment will be applied via a non-contact method, with the laser applicator held 12-18 inches above the participant's skin.
Study NCT02405377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hydration
Description: Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.
Study NCT02405377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hydration
Description: Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.
Study NCT02405377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visipaque
Description: All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
Study NCT02405377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque
Description: All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
Study NCT02405377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride ﬂuid administration
Study NCT02405377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride ﬂuid administration
Study NCT02405377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-French catheter
Study NCT00433043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker (carvedilol or metoprolol succinate)
Description: Both groups get CRT. Group 1 is uptitrated to target dose beta blocker after CRT. Group 2 maintains their b-blocker dose from study entry.
Study NCT00433043 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRT (cardiac resynchronization therapy)
Description: Both arms
Study NCT00786370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Propofol or dexmedetomidine infusion will be started according to the randomized treatment allocation. The propofol group will receive a bolus of 2mg midazolam and 100mcg fentanyl and then continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved. The dexmedetomidine group will receive a bolus of dexmedetomidine 1mcg/kg for 10 minutes and then a continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
Study NCT00786370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved
Study NCT00786370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexemedetomidine
Description: continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
Study NCT02141828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPZ-5676
Description: 28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
Study NCT04986319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum vitamin D assay
Description: Trained phlebotomists will collect 10 cc of a Blood sample. Specimen will be preserved at -40ºc for batch analysis.~S Vitamin D, S iPTH, S Calcium, S Alkaline Phosphatase, S PO4, S Mg, S Albumin and S Creatinine will be done in BIRDEM laboratory. Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: The ARCHITECT 25-OH Vitamin D assay is a chemiluminescent micro-particle immunoassay (CMIA). This technology is used for the quantitative analysis of 25(OH) D and aid in the assessment of vitamin D sufficiency.
Study NCT03765034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constrain-induced Movement Therapy
Description: 8-week therapy program utilizing constraint of the unaffected arm
Study NCT03765034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Occupational Therapy
Description: 8-week therapy program without constraint of the unaffected arm
Study NCT03765034 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Occupational Therapy
Description: 8-week therapy program without constraint of the unaffected arm
Study NCT04000854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide (Calacept)
Description: Long-term follow up of pulp regenerative treatment using two different root canal dressings: calcium hydroxide and chlorhexidin digluconate in immature necrotic traumatized incisiors
Study NCT04562818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: Determine the number of center that are able to process PCR or FISH/Karyotype for PML/RAR or t(15;17)
Study NCT04562818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular and Karyotype
Description: To realize the need of having more center we the technology to perform all of these tests
Study NCT04562818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Leucocytes
Study NCT00958906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab (intravitreal, 2.0mg/0.05ml)
Description: One injection of intravitreal infliximab (2.0mg/0.05ml).
Study NCT03101332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality cognitive behavior therapy
Description: Cognitive interventions targeted to change catastrophic misinterpretations of the physiological symptoms that occur during a panic attack.~Exposure via Virtual Reality to filmed sequences of environments typically feared by agoraphobic patients such as underground station/train, a tunnel, a lift and a public square, as well as exposure to the feared symptoms that occur in a typical panic attack.~Interventions are delivered by a psychologist in face-to-face sessions.
Study NCT01506804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: Steroid injection X 2 and 10 weeks exercise program of painful shoulder vs exercise program of contralateral shoulder
Study NCT01506804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Steroid injection X 2 and 10 weeks exercise program of painful shoulder vs exercise program of contralateral shoulder
Study NCT00409552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality based distraction
Description: Participants will undergo virtual reality based distraction using the head display while they go through the pain process.
Study NCT00409552 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR with flat projection display
Description: VR with flat projection display
Study NCT00409552 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-interactive video with head display
Description: non-interactive video with head display
Study NCT00409552 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-interactive video with with flat projection display
Description: non-interactive video with with flat projection display
Study NCT04323657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-110 T Cells
Description: TC-110 T Cells
Study NCT04323657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Flu/Cy Lymphodepletion
Study NCT04323657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Flu/Cy Lymphodepletion
Study NCT01136083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.
Study NCT01136083 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
Study NCT00517088 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPAQ
Study NCT00659737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aprepitant
Description: 40mg tablet
Study NCT00659737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: 1.5 mg patch delivering transdermally in vivo approx. 1.0mg over 3 days
Study NCT00351052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecroliums cream 1 % bid.
Study NCT00351052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle control (placebo) bid.
Study NCT02510677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: myocardial perfusion scintigraphy
Study NCT02037308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread
Study NCT02037308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bread
Study NCT01823913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation
Description: A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg
Study NCT01823913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference formulation
Description: A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg
Study NCT01897818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: communication system P300 Speller
Study NCT01157403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous transplantation
Description: Autologous transplantation of bone marrow mesenchymal stem cells (approximately 2.5 x 106 cells/kg body weight) intravenously
Study NCT01956916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: Capsules containing lyophilized 6x10\^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months
Study NCT01956916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months
Study NCT00853632 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES
Description: Mitral valve replacement
Study NCT01908803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-60371/AL-817 otic suspension
Study NCT01908803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension
Description: CIPRODEX®
Study NCT03677453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Perioperative Teaching Platform
Description: An active video format will be used to provide instructions for navigating the hospital; describe induction of anesthesia and the surgical procedure; and provide post-surgery and post-discharge instructions for pain management.
Study NCT00742235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ergocalciferol
Description: Ergocalciferol 50,000 IU given every other day for 5 total doses
Study NCT00485134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 240 µg Shigella flexneri 2a Invaplex 50 vaccine
Description: Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
Study NCT00485134 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 240 µg Shigella flexneri 2a Invaplex 50 vaccine
Description: Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
Study NCT00485134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 480 µg Shigella flexneri 2a Invaplex 50 vaccine
Description: Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
Study NCT00485134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 690 Shigella flexneri 2a Invaplex 50 vaccine
Description: Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
Study NCT00485134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Shigella challenge strain
Description: 300 colony forming units (CFU) of Shigella challenge strain, Shigella flexneri 2a strain 2457T
Study NCT00485134 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Shigella challenge strain
Description: 300 colony forming units (CFU) of Shigella challenge strain, Shigella flexneri 2a strain 2457T
Study NCT00126334 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Packed Red Blood Cell Transfusion
Description: transfusion of 1 unit of PRBCs
Study NCT00126334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Packed Red Blood Cell Transfusion
Description: transfusion of 1 unit of PRBCs
Study NCT02192281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Playworks
Description: The Playworks program places full-time coaches in low-income schools to provide opportunities for organized play during recess and throughout the school day.
Study NCT02586649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium Bromide
Description: Tiotropium bromide is an anticholinergic used to study bronchodilatation and improvement of pulmonary function in tetraplegic patients
Study NCT02586649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide
Description: Tiotropium bromide is an anticholinergic used to study bronchodilatation and improvement of pulmonary function in tetraplegic patients